Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 15,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the sale, the chief executive officer directly owned 607,133 shares in the company, valued at $76,674,826.57. This trade represents a 2.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, June 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00.
• On Tuesday, April 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $131.27 on Friday. Gilead Sciences, Inc. has a twelve month low of $107.75 and a twelve month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a market cap of $162.98 billion, a P/E ratio of 17.88 and a beta of 0.32. The company’s 50-day simple moving average is $129.48 and its 200 day simple moving average is $134.56.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GILD. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Leerink Partners cut their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research note on Wednesday, May 20th. Daiwa Securities Group lowered their target price on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Finally, Truist Financial reiterated a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $158.41.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of the business. Brighton Jones LLC lifted its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $215,000. Sivia Capital Partners LLC lifted its position in shares of Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares in the last quarter. Ieq Capital LLC lifted its position in shares of Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC grew its stake in shares of Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 674 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.